Last reviewed · How we verify
NCT06634225: IMUSEP
Use of Inertial Units in Patient With Multiple Sclerosis (IMUSEP)
trial testing Usual care (as recommended by the Haute Authorité de Santé (HAS)) and medical device test in Multiple Sclerosis in 70 participants. Completed in 19 December 2025.
19 December 2025
Quick facts
| Lead sponsor | Lille Catholic University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 70 |
| Start date | 8 November 2024 |
| Primary completion | 19 December 2025 |
| Estimated completion | 19 December 2025 |
| Sites | 2 locations across France |
Drugs / interventions tested
- Usual care (as recommended by the Haute Authorité de Santé (HAS)) and medical device test
- Usual care (as recommended by the Haute Authorité de Santé (HAS)) and medical device test
Conditions studied
- Multiple Sclerosis — all drugs for Multiple Sclerosis →
- Medical Device — all drugs for Medical Device →
- Coordination and Balance Disturbances — all drugs for Coordination and Balance Disturbances →
Sponsor
Lille Catholic University
Who can join
Adults 18 to 65, any sex, with Multiple Sclerosis or Medical Device. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this case control study is to evaluate the use of inertial navigation systems to detect and characterize early locomotor disorders in patients with multiple sclerosis (MS). The study aims to: • Validate the contribution and inefficiency indexes obtained by the Trigno® Avanti Sensor inertial units, in comparison with indexes calculated with 3D motion analysis during walking and tandem in early-stage MS patients. Researchers will compare MS patients, to healthy controls.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06634225
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Multiple Sclerosis
Currently open trials in the same condition.
- NCT07507084 — The Effect of Internal- or External-Focused Exercise Training, Administered in Conjunction With a Cognitive Task, on Wal · NA · recruiting
- NCT07524231 — Evaluation of the Effects of Laughter Yoga · NA · recruiting
- NCT07489794 — URINARY INCONTINENCE AND PELVIC FLOOR MUSCLE ACTIVITY IN MULTIPLE SCLEROSIS · recruiting
- NCT07236684 — Identification of Factors Related to UI in Patients With MS and EMG Assessment of PFM Activity · recruiting
- NCT07500727 — Skeletal Muscle Aging and Responsiveness in Aged People With MS · NA · recruiting
Other Lille Catholic University trials
Trials by the same sponsor.
- NCT06116929 — Hodgkin's Disease and Chemotherapy Before 40 Years · NA · not yet recruiting
- NCT05208099 — Study of the Immunomodulation in the Hidradenitis Suppurativa and Evaluation of a New Therapeutic Strategy · not yet recruiting
- NCT06318923 — Social and Moral Cognition in Multiple Sclerosis · NA · unknown
- NCT06083415 — Early Breast Growth in Girls Aged 6 to 8 Years in the Current Environmental Context · NA · recruiting
- NCT05607797 — Genetic of Chronic Kidney Disease and Gout in New Caledonia · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06634225 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Lille Catholic University
- Last refreshed: 12 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06634225.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing